New Milton, Hampshire, UK, 26th April 2010 – Genetix, a leading provider of solutions for imaging and image analysis, announces that Vanderbilt Monoclonal Antibody Core (VMAC), Vanderbilt University, has become the 100th facility to purchase its ClonePix™ FL system.
Used for screening and selection of secretory cell lines, the ClonePix FL system can significantly reduce the time and costs associated with recombinant protein generation. VMAC will use the system to support its monoclonal and polyclonal antibody generation, purification, and characterization technical advice and services, and also its recombinant protein production and purification services.
Dr. Robert Carnahan, Director, VMAC, said: “Our aim at VMAC is to provide a centre of expertise in all areas of monoclonal antibody production and recombinant protein technology. It is vital that we are able to access state of the art technology such as the ClonePix FL system, in order to provide the best service for investigators both within Vanderbilt and beyond.”
Charles de Rohan, Head of the Genetix Business Unit within Leica Microsystems, commented: “We’re delighted that the benefits of ClonePix FL systems are recognized by so many laboratories. The VMAC is a highly prestigious institute and its decision to invest in this technology is testament to the value it brings to antibody and recombinant protein production.” About Genetix (www.genetix.com)
Headquartered in New Milton, UK, with offices in the UK, US, Germany and Japan, Genetix is an independent business unit within Leica Microsystems. The company provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis in the life science and clinical markets.
In research, pharmaceutical and biotherapeutic development, Genetix systems continue to establish industry standards in areas such as picking microbial colonies for genomic studies or screening and selection of mammalian cell lines. Other systems use imaging platforms to monitor cell growth, evaluate cellular response and quantify tissue biomarkers.
In the clinical market, Genetix holds a leading position with thousands of systems based on its CytoVision® platform used in cytogenetics laboratories throughout the world.
Through its expertise in robotics, cell and molecular biology, image analysis and interpretation, supported by a strong IP portfolio, Genetix is committed to the continual development of innovative solutions.
About Leica Microsystems (www.leica-microsystems.com)
Leica Microsystems is a leading global designer and producer of innovative, high-tech, precision optical systems for the analysis of microstructures. It is one of the market leaders in each of its business areas: Microscopy, Confocal Laser Scanning Microscopy with corresponding Imaging Systems, Specimen Preparation, and Medical Equipment.
The company manufactures a broad range of products for numerous applications requiring microscopic imaging, measurement, and analysis. It also offers system solutions for life science including biotechnology and medicine, research and development of raw materials, and industrial quality assurance. The company is represented in over 100 countries with 11 manufacturing facilities in 8 countries, sales and service organizations in 19 countries and an international network of dealers. The international management is headquartered in Wetzlar, Germany.
